Swedish Orphan Biovitrum AB (publ)
STO:SOBI

Watchlist Manager
Swedish Orphan Biovitrum AB (publ) Logo
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
Watchlist
Price: 290 SEK -0.21% Market Closed
Market Cap: 99.8B SEK
Have any thoughts about
Swedish Orphan Biovitrum AB (publ)?
Write Note

Relative Value

The Relative Value of one SOBI stock under the Base Case scenario is 368.79 SEK. Compared to the current market price of 290 SEK, Swedish Orphan Biovitrum AB (publ) is Undervalued by 21%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

SOBI Relative Value
Base Case
368.79 SEK
Undervaluation 21%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
23
vs Industry
67
Median 3Y
3.8
Median 5Y
3.6
Industry
7.7
Forward
3.7
vs History
20
vs Industry
4
Median 3Y
25.5
Median 5Y
21.7
Industry
22.7
Forward
27.6
vs History
26
vs Industry
10
Median 3Y
14.6
Median 5Y
13.1
Industry
21.6
vs History
vs Industry
10
Median 3Y
9.2
Median 5Y
7.9
Industry
25.2
vs History
34
vs Industry
34
Median 3Y
2.6
Median 5Y
2.6
Industry
2.5
vs History
36
vs Industry
55
Median 3Y
4.2
Median 5Y
4.2
Industry
7.7
Forward
4.1
vs History
47
vs Industry
50
Median 3Y
5.6
Median 5Y
5.5
Industry
9
vs History
42
vs Industry
9
Median 3Y
12.1
Median 5Y
11.2
Industry
4.2
Forward
11.7
vs History
34
vs Industry
5
Median 3Y
19.4
Median 5Y
16.5
Industry
4.1
Forward
20.2
vs History
30
vs Industry
9
Median 3Y
16.2
Median 5Y
15.7
Industry
5.7
vs History
41
vs Industry
6
Median 3Y
23.6
Median 5Y
22.3
Industry
3.6
vs History
20
vs Industry
52
Median 3Y
1.4
Median 5Y
1.4
Industry
4.6

Multiples Across Competitors

SOBI Competitors Multiples
Swedish Orphan Biovitrum AB (publ) Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
SE
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
99.6B SEK 3.9 28.3 11.5 18.6
FR
Pharnext SCA
OTC:PNEXF
6T USD 38 083 264.3 -181 004.1 -219 796.6 -217 288.5
US
Abbvie Inc
NYSE:ABBV
312.7B USD 5.6 61.5 15.3 23.6
US
Amgen Inc
NASDAQ:AMGN
158.3B USD 4.9 37.4 17.5 33.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.9B USD 10.9 -241.6 24 25.2
US
Gilead Sciences Inc
NASDAQ:GILD
112.4B USD 4 891.9 9.9 9.9
US
Epizyme Inc
F:EPE
94.1B EUR 1 849.9 -472 -514.1 -500.3
AU
CSL Ltd
ASX:CSL
133.6B AUD 5.9 32.9 20.3 25.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82.6B USD 5.9 17.8 16.2 18
US
Seagen Inc
F:SGT
39.3B EUR 17.8 -54.6 -58.7 -53
NL
argenx SE
XBRU:ARGX
34.5B EUR 18.5 -129.9 -104.5 -76.2
P/E Multiple
Earnings Growth
SE
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
Average P/E: 178.3
28.3
213%
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -181 004.1 N/A
US
Abbvie Inc
NYSE:ABBV
61.5
412%
US
Amgen Inc
NASDAQ:AMGN
37.4
73%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -241.6
42%
US
Gilead Sciences Inc
NASDAQ:GILD
891.9
75%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -472 N/A
AU
CSL Ltd
ASX:CSL
32.9
65%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.8
43%
US
S
Seagen Inc
F:SGT
Negative Multiple: -54.6 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -129.9 N/A
EV/EBITDA Multiple
EBITDA Growth
SE
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
Average EV/EBITDA: 16.4
11.5
72%
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -219 796.6 N/A
US
Abbvie Inc
NYSE:ABBV
15.3
29%
US
Amgen Inc
NASDAQ:AMGN
17.5
62%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24
43%
US
Gilead Sciences Inc
NASDAQ:GILD
9.9
16%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -514.1 N/A
AU
CSL Ltd
ASX:CSL
20.3
42%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.2
35%
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.7 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -104.5 N/A
EV/EBIT Multiple
EBIT Growth
SE
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
Average EV/EBIT: 22
18.6
113%
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -217 288.5 N/A
US
Abbvie Inc
NYSE:ABBV
23.6
88%
US
Amgen Inc
NASDAQ:AMGN
33.1
93%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.2
44%
US
Gilead Sciences Inc
NASDAQ:GILD
9.9
29%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -500.3 N/A
AU
CSL Ltd
ASX:CSL
25.3
55%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18
54%
US
S
Seagen Inc
F:SGT
Negative Multiple: -53 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -76.2 N/A

See Also

Discover More
Back to Top